Clicky

Genexine Inc(095700)

Description: Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.


Keywords: Biotechnology Diabetes Clinical Trial Clinical Research Anemia Clinical Pharmacology Cervical Cancer Treatment Of Diabetes Neutropenia Immunotherapeutics Treatment Of Cervical Cancer G3

Home Page: www.genexine.com

Korea Bio Park Building B
Seongnam, 13488
South Korea
Phone: 82 3 1628 3200


Officers

Name Title
Dr. Young Chul Sung Ph.D. Founder, Chairman of Directors and Chief Technology Officer
Dr. Jungwon Woo Ph.D. Chief Exec. Officer
Mr. Sung June Hong CPA VP, CFO & COO
Dr. Jai-Hyun Kwon Director of Corp. Devel. & Transaction
Dr. You Suk Suh Ph.D. Head of Research Institute and Representative Director
Dr. Jae Chan Park Ph.D. Exec. VP of Alliance Operation
Dr. Kyu Don Kim Ph.D. Exec. VP of Bus.
Dr. Sung Hee Lee Ph.D. Head of Bio Research Institute and Exec. VP

Exchange: KQ

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 10.8429
IPO Date:
Fiscal Year End: December
Full Time Employees: 123
Back to stocks